Novel therapy for pediatric and adolescent kidney cancer

Amy L. Walz*, Conrad V. Fernandez, James I. Geller

*Corresponding author for this work

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Pediatric and adolescent renal tumors account for approximately 7% of all new cancer diagnoses in the USA each year. The prognosis and treatment are varied based on factors including the underlying histology and tumor stage, with survival rates ranging from greater than 90% in favorable histology Wilms tumor to almost universally fatal in other disease types, including those patients with advanced stage malignant rhabdoid tumor and renal medullary carcinoma. In recent years, our understanding of the underlying genetic drivers of the different types of pediatric kidney cancer has dramatically increased, opening the door to utilization of new targeted biologic agents alone or in combination with conventional chemotherapy to improve outcomes. Several ongoing clinical trials are investigating the use of a variety of targeted agents in pediatric patients with underlying genetic aberrations. In this manuscript, the underlying biology and early phase clinical trials relevant to pediatric renal cancers are reviewed.

Original languageEnglish (US)
Pages (from-to)643-655
Number of pages13
JournalCancer and Metastasis Reviews
Volume38
Issue number4
DOIs
StatePublished - Dec 1 2019

    Fingerprint

Keywords

  • Kidney cancer
  • Novel therapy
  • Pediatric
  • Rhabdoid tumor
  • Wilms tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this